Anti-apoptotic hPEBP4 silencing promotes TRAIL-induced apoptosis of human ovarian cancer cells by activating ERK and JNK pathways

International Journal of Molecular Medicine

Volumn 18, Issue 3, 2006, Pages 505-510

  Li, Peng ^a,b   Wang, Xiaojian ^c   Li, Nan ^b   Kong, Huabei ^a   Guo, Zhenhong ^b   Liu, Shuxun ^b   Cao, Xuetao ^b,c  

^a SHANDONG UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

Apoptosis; MAPK; Ovarian carcinoma; Phosphatidylethanolamine binding protein; TRAIL

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; DNA BINDING PROTEIN; ENHANCER BINDING PROTEIN AP 4; ENHANCER-BINDING PROTEIN AP-4; MAP2K1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; RAF PROTEIN; TNFSF10 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL CULTURE; DRUG EFFECT; FEMALE; GENE EXPRESSION; HUMAN; METABOLISM; OVARY TUMOR; PHYSIOLOGY; PROTEIN BINDING; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DNA-BINDING PROTEINS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 4; MEMBRANE GLYCOPROTEINS; OVARIAN NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-RAF; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750584261     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.18.3.505     Document Type: Article

References (31)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
2. Sifri R, Gangadharappa S and Acheson LS: Identifying and testing for hereditary susceptibility to common cancers. CA Cancer J Clin 54: 309-326, 2004.
3. Barnes MN, Grizzle WE, Grubbs CJ and Partridge EE: Paradigms for primary prevention of ovarian carcinoma. CA Cancer J Clin 52: 216-225, 2002.
4. Lehnert M: Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 32A: 912-920, 1996.
5. Ashkenazi A and Dixit V: Death receptors: signaling and modulation. Science 281: 1305-1308, 1998.
6. Ashkenazi A, Pai RC, Fong S, et al: Safety and anti-tumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
7. Walczak H, Miller RE, Ariail K, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
8. Cuello M, Ettenberg SA, Nau MM and Lipkowitz S: Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 81: 380-390, 2001.
9. Wang X, Li N, Liu B, et al: A novel human phosphatidylethanolamine- binding protein resists TNFα-induced apoptosis by inhibiting mitogen-activated protein kinase pathway activation and phosphatidylethanolamine externalization. J Biol Chem 279: 45855-45864, 2004.
10. Wang X, Li N, Li H, et al: Silencing of human phosphatidylethanolamine- binding protein 4 sensitizes breast cancer cells to TNFα-induced apoptosis and cell growth arrest. Clin Cancer Res 11: 7545-7553, 2005.
11. Lin Y, Devin A, Cook A, et al: The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol 20: 6638-6645, 2000.
12. Wen L, Zhuang L, Luo X and Wei P: TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. J Biol Chem 278: 39251-39258, 2003.
13. Tran SE, Holmstrom TH, Ahonen M, Kahari VM and Eriksson JE: MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem 276: 16484-16490, 2001.
14. Ohtsuka T and Zhou T: Bisindolylmaleimide VIII enhances DR5- mediated apoptosis through the MKK4/JNK/p38 kinase and the mitochondrial pathways. J Biol Chem 277: 29294-29303, 2002.
15. Samanta AK, Huang HJ, Bast RC Jr and Liao WS: Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB. J Biol Chem 279: 7576-7583, 2004.
16. Wang S and El-Deiry WS: TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628-8633, 2003.
17. Christ O, Seiter S, Matzku S, Burger C and Zoller M: Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy. Clin Cancer Res 7: 985-998, 2001.
18. Bergmann A, Agapite J, McCall K and Steller H: The Drosophila gene hid is a direct molecular target of Ras-dependent survival signaling. Cell 95: 331-341, 1998.
19. Tang G, Minemoto Y, Dibling B: Inhibition of JNK activation through NF-kappaB target genes. Nature 414: 313-317, 2001.
20. Han Z, Boyle DL, Chang L, et al: c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 108: 73-81, 2001.
21. Blank SV, Chang R, Muggia F, et al: Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancer. Oncology 19: 553-559, 2005.
22. Santin AD, Cane S, Bellone S, et al: Treatment of chemotherapy- resistant human ovarian cancer xenografts in C.B-17/ SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res 65: 4334-4342, 2005.
23. Berchuck A, Iversen ES, Lancaster JM, et al: Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 11: 3686-3696, 2005.
24. Chan JK, Pham H, You XJ, et al: Suppression of ovarian cancer cell tumorigenicity and evasion of cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. Cancer Res 65: 3243-3248, 2005.
25. Zornig M, Hueber A, Baum W and Evan G: Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 1551: F1-F37, 2001.
26. Ibrado AM, Liu L and Bhalla K: Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells. Cancer Res 57: 1109-1115, 1997.
27. Wall NR and Shi Y: Small RNA: can RNA interference be exploited for therapy? Lancet 362: 1401-1403, 2003.
28. Trougakos IP, So A, Jansen B, et al: Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 64: 1834-1842, 2004.
29. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
30. Wen-Hui H, Holly J and Hong-Bing S: Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-κB and JNK activation and apoptosis through distinct pathways. J Biol Chem 274: 30603-30610, 1999.
31. Sah NK, Munshi A, Kurland JF, et al: Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase. J Biol Chem 278: 20593-20602, 2003.